NCT02346747 2025-10-29
VITAL
Gradalis, Inc.
Phase 2 Active not recruiting
Clinical Trials
18 trialsNCT00019097 2024-03-04
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006478 2023-09-18
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Terminated
NCT03073525 2023-04-05
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
Phase 2 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT02725489 2021-01-27
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Mary Crowley Medical Research Center
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02639234 2017-07-31
Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Gradalis, Inc.
Phase 2 Withdrawn
NCT00436930 2014-01-10
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00093522 2013-12-19
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003185 2013-12-04
Biological Therapy in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003386 2013-04-11
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Phase 2 Terminated
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00004022 2013-04-05
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00004024 2013-04-05
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00343447 2012-05-03
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT00002454 2011-07-26
Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
National Cancer Institute (NCI)
Phase 2 Unknown